Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgM-FAT: Personalized vs Standard Dose IgM-enriched Immunoglobulin in Septic Shock
NCT04182737Phase 3Unknown
- Start
- May 2020
- Primary completion
- Feb 2022
- Modality
- IgG Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Pentaglobin in septic shock. Status: unknown.
02
Drugs
Pentaglobin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT04182737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182737.